Education — Layer 9

Chart Timing for Biotech PDUFA Events

A 97% probability of approval doesn't tell you when to enter. Here's how to read a chart before a PDUFA date — and why the setup matters as much as the score.

⚠️ Educational content. Not investment advice. Biotech PDUFA events carry substantial binary risk. All trade timing decisions are yours.

The Problem PoA Doesn't Solve

Two stocks. Both have 80% probability of approval. Both are in your scanner as STRONG. Same indication, similar market cap. You have capital for one trade.

Stock A has run up 45% in the last 30 days. It's trading near its 52-week high. The options market has already priced in massive approval odds. Every biotech trader in every forum is talking about it.

Stock B has gone sideways for three weeks. It's in the middle of its 52-week range. Volume has been quiet. Nobody is posting about it. The price action looks like a coil — tight range, building energy, waiting for a catalyst.

These are completely different trades. The probability of approval is identical. The risk/reward is not. Stock A's upside on approval is limited because approval is already priced in. Stock B's upside on approval is real because the market hasn't fully priced it yet.

This is what the Chart Setup layer in Submarine Catalyst scores. Layer 9 in the model. The question the other eight layers can't answer: is the chart ready right now?

The Five Chart Setup Labels

✅ READY (Score 70-100)
Consolidating near support. Mid-range in 52-week history. Gentle uptrend (0-15% in 30 days). PDUFA within 1-2 weeks. This is the optimal setup — chart is coiled, energy building, market hasn't fully priced in approval. Best risk/reward for entering a PDUFA position.
📡 COILING (Score 60-69)
Tight range forming, compression detected in recent candles vs prior period. Not broken out yet — the coil is still building. Watch for volume expansion as the signal. This is the pre-READY stage. Consider a smaller starter position and add on the breakout.
⚠️ BUILDING (Score 50-59)
Uptrend in progress, 15-30% in the last 30 days. Still a reasonable entry but the easy money may be made. Don't chase — if the stock has already started moving, the question is how much is already priced in. Reduce position size vs a READY or COILING setup.
🚨 EXTENDED (Score 30-49)
Already ran 30-50%+ into the catalyst. The approval may be priced in. Even if the drug gets approved the stock can drop — this is the sell-the-news setup. RCKT ran into its PDUFA and dropped 20% on approval. EXTENDED + HIGH STN = avoid or significantly reduce size.
❌ WEAK (Score 0-29)
Downtrend. The chart is fighting the catalyst. Something the market knows — dilution, failed data, FDA feedback — is creating persistent selling pressure. Avoid regardless of PoA score. A 90% approval probability doesn't overcome a stock that institutions are consistently selling.
— UNKNOWN
Insufficient price data or API timeout. Check the ticker directly on a charting platform. Score not available for this event.

The Consolidation Pattern — What "Coiling" Means

A consolidation happens when a stock's daily price range compresses over 10-20 days. Instead of making new highs or lows, the stock trades in a tight band — like a spring being compressed before release.

Before a binary catalyst like a PDUFA date, consolidation is a specific signal: the market is waiting. Traders who want in have already built their positions. Sellers have already sold. What remains is a tight range of holders waiting for the FDA decision. When the decision comes, the spring releases.

The Submarine Catalyst scanner detects consolidation by comparing the average daily range of the last 10 days to the prior 10 days. If the recent range is 35%+ smaller than the prior period, the stock is flagged as COILING. This is the pattern Evan described when he said "VERA had been building a tight range waiting to pop for weeks" — the exact pattern the scanner now detects and scores automatically.

What to look for in a COILING setup

The stock has stopped making new highs and lows. Daily candles are getting shorter. Volume is declining (the quiet before the storm). The stock is trading within a narrowing range. The PDUFA date is 1-3 weeks away. This is the most favorable technical setup for a PDUFA catalyst trade.

The 52-Week Range Position

Where a stock sits in its 52-week range tells you how much room it has to move and how much expectation is already built into the price.

Near the 52-week low (bottom 20%): Something is wrong — the market has been selling this stock for months. Unless you understand why, avoid. Even a positive PDUFA outcome may not overcome persistent institutional selling.

Mid-range (35-65%): Optimal. The stock hasn't been destroyed by sellers and hasn't been inflated by buyers. There's room to move in both directions. Approval has upside potential. CRL is a known risk but not catastrophic from this level.

Near the 52-week high (top 15%): Approval is largely priced in. The catalyst has been a known event for months and investors have been accumulating. On approval, the "buy the rumor sell the news" dynamic is most severe. STN risk is highest here.

The 30-Day Trend

The 30-day price trend shows how aggressively the market has been pricing in the upcoming PDUFA event. The sweet spot is a controlled 0-15% uptrend — the market is acknowledging the catalyst without fully pricing it in.

When the run-up kills the trade

RCKT ran into its March 28, 2026 PDUFA date after a significant pre-announcement run-up. The scanner flagged it as HIGH STN Risk. The drug got approved. The stock dropped 20%. The approval was correct — the entry timing was wrong. A 30-day trend above 30% almost always means the risk/reward has shifted against the long position. The easy money was made by whoever bought months earlier.

How to Use Chart Setup With the Other Layers

Chart Setup is the ninth layer in the Net Edge Score. It doesn't override the other eight — it refines them. Here's how to read the combination:

Best setup: READY + HIGH PoA + LOW STN + MINIMAL Dilution
COILING or READY chart · 70-85% PoA · LOW STN Risk · No recent SEC dilution filings
→ Full conviction sizing. The model, the risk layers, AND the chart all agree.
Avoid: EXTENDED + HIGH PoA + HIGH STN
EXTENDED chart (already ran 40%+) · 85%+ PoA · HIGH STN Risk
→ Approval is fully priced in. If approved, stock likely drops. Classic RCKT pattern.
→ Skip or play the short side of approval.
Watch carefully: WEAK chart + HIGH PoA
WEAK or declining chart · 80%+ PoA
→ Disconnect between model and market. Either the model is missing something (like REPL's CMC issue)
OR the market is wrong and there's an opportunity. Investigate before entering.

Why This Matters More for Small-Cap Biotech

Large-cap pharma stocks like MRK or SNY barely move on individual PDUFA decisions because one drug is a small fraction of their revenue. The chart setup layer is most valuable for small-cap and mid-cap biotechs where a single PDUFA can move the stock 30-100% in either direction.

In small-cap biotech, the institutional money moves before the decision. They build positions over weeks, the stock coils, and then resolves violently on the PDUFA date. Retail traders who understand this pattern — enter during the coil, not after the breakout — capture the same move institutions do. Retail traders who don't — who chase after the stock has already run 40% — become the exit liquidity for those same institutions.

The Chart Setup score is the scanner's attempt to quantify which side of that equation you're on at any given entry point.

See how sell-the-news risk interacts with chart setup: How Institutions Trade PDUFA Events →

FDA approval rates by indication: Approval Rates by Indication →

Full methodology: Beginner's Guide →

Access the Scanner — $29.99/month

9 scoring layers · Chart Setup live on every event · 870+ companies